Takara Bio applies to FDA for phase II testing of oncolytic virus-based cancer drug (HF10)

The target is metastatic malignant melanoma, and the treatment is based on Ipilimumab and HF10 attenuated Herpes simplex virus. The HF10-based developments were acquired from M’s Science Corporation in 2010.

Takara Bio news release, May 1, 2014